Hypertension increases the incidence of adverse cardiovascular events such as stroke, heart failure, and coronary artery disease. Studies have shown that treatment of even mild hypertension can reduce the occurrence of these adverse cardiovascular events--particularly stroke, congestive heart failure, and progression to more severe hypertension. Patients with newly diagnosed hypertension can be treated pharmacologically with thiazide-type diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, or calcium channel blockers. Nonpharmacologic therapy such as weight reduction can also play an important role in treatment. Additional study is needed to identify optimal drug treatment regimens and to clarify the association between treatment of hypertension and the occurrence of adverse effects from ischemic heart disease.
Download full-text PDF |
Source |
---|
Dig Dis Sci
January 2025
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan, 70401, Taiwan.
Aim: Sarcopenic obesity (SO) is associated with adverse outcomes in diseased patients. This study aimed to examine the prevalence and risks associated with SO, with a focus on the impact of SO on cardiovascular risk in patients with MASLD.
Materials And Methods: In this cross-sectional study, patients with MASLD were prospectively enrolled.
Drugs Aging
January 2025
Program for the Care and Study of the Aging Heart, Department of Medicine, Weill Cornell Medicine, 420 East 70th St, New York, NY, LH-36510063, USA.
There are several pharmacologic agents that have been touted as guideline-directed medical therapy for heart failure with preserved ejection fraction (HFpEF). However, it is important to recognize that older adults with HFpEF also contend with an increased risk for adverse effects from medications due to age-related changes in pharmacokinetics and pharmacodynamics of medications, as well as the concurrence of geriatric conditions such as polypharmacy and frailty. With this review, we discuss the underlying evidence for the benefits of various treatments in HFpEF and incorporate key considerations for older adults, a subpopulation that may be at higher risk for adverse drug events.
View Article and Find Full Text PDFCardiovasc Toxicol
January 2025
RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
The rapid development and deployment of mRNA and non-mRNA COVID-19 vaccines have played a pivotal role in mitigating the global pandemic. Despite their success in reducing severe disease outcomes, emerging concerns about cardiovascular complications have raised questions regarding their safety. This systematic review critically evaluates the evidence on the cardiovascular effects of COVID-19 vaccines, assessing both their protective and adverse impacts, while considering the challenges posed by the limited availability of randomized controlled trial (RCT) data on these rare adverse events.
View Article and Find Full Text PDFEur J Cardiovasc Nurs
January 2025
Professor, College of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Aims: A randomized controlled trial was conducted to examine the effects of a home-based multicomponent exercise programme on frailty in patients who underwent cardiac surgery.
Methods And Results: A convenience sample of 92 patients who underwent cardiac surgery at two medical centres in Taiwan were recruited and randomly allocated to the intervention (n = 46) and control (n = 46) groups. The intervention group underwent a 12-week home-based multicomponent exercise programme, including individual nursing consultation, home-based exercise intervention, nutritional assessment and guidance, and continuous support.
FASEB J
January 2025
National Key Laboratory of Space Medicine, China Astronaut Research and Training Center, Beijing, China.
Microgravity-induced cardiac remodeling and dysfunction present significant challenges to long-term spaceflight, highlighting the urgent need to elucidate the underlying molecular mechanisms and develop precise countermeasures. Previous studies have outlined the important role of miRNAs in cardiovascular disease progression, with miR-199a-3p playing a crucial role in myocardial injury repair and the maintenance of cardiac function. However, the specific role and expression pattern of miR-199a-3p in microgravity-induced cardiac remodeling remain unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!